GlaxoSmithKline moving forward with Ebola vaccine

Fortune

GlaxoSmithKline, the UK’s largest drugmaker, reported its third quarter earnings Wednesday and revealed earnings that beat analysts’ estimates even as profits dipped, the company announced. Here’s what else you need to know about.

What you need to know: Glaxo [fortune-stock symbol=”GSK”] failed to post a profit gain after facing currency headwinds and slowing sales of its No. 1 drug Advair after it lost patent protection. The asthma medication is the company’s best-selling product, and it has been losing market share in the U.S. faster than the company anticipated. It’s two new respiratory drugs, Breo and Anoro, haven’t caught on as quickly as the company would like in order to replace slipping sales of Advair.

Glaxo said it will explore an initial public offering of ViiV Healthcare, a joint venture with Pfizer [fortune-stock symbol=”PFE”] and Shionogi that focuses on HIV drug development. The offering would sell a minority stake in the…

View original post 219 more words

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s